Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers.

Williams MM, Elion DL, Rahman B, Hicks DJ, Sanchez V, Cook RS.

Oncotarget. 2019 Oct 9;10(52):5389-5402. doi: 10.18632/oncotarget.27070. eCollection 2019 Sep 10.


Activation of RIG-I signaling to increase the pro-inflammatory phenotype of a tumor.

Elion DL, Cook RS.

Oncotarget. 2019 Mar 22;10(24):2338-2339. doi: 10.18632/oncotarget.26729. eCollection 2019 Mar 22. No abstract available.


Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1.

Werfel TA, Elion DL, Rahman B, Hicks DJ, Sanchez V, Gonzales-Ericsson PI, Nixon MJ, James JL, Balko JM, Scherle PA, Koblish HK, Cook RS.

Cancer Res. 2019 Jan 1;79(1):171-182. doi: 10.1158/0008-5472.CAN-18-1106. Epub 2018 Nov 9.


Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers.

Elion DL, Jacobson ME, Hicks DJ, Rahman B, Sanchez V, Gonzales-Ericsson PI, Fedorova O, Pyle AM, Wilson JT, Cook RS.

Cancer Res. 2018 Nov 1;78(21):6183-6195. doi: 10.1158/0008-5472.CAN-18-0730. Epub 2018 Sep 17.


Genetic and Phenotypic Diversification of Heterogeneous Tumor Populations.

Elion DL, Cook RS.

Trends Mol Med. 2018 Aug;24(8):655-656. doi: 10.1016/j.molmed.2018.06.003. Epub 2018 Jun 28.


Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment.

Elion DL, Cook RS.

Oncotarget. 2018 Jun 22;9(48):29007-29017. doi: 10.18632/oncotarget.25626. eCollection 2018 Jun 22. Review.


ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation.

Williams MM, Vaught DB, Joly MM, Hicks DJ, Sanchez V, Owens P, Rahman B, Elion DL, Balko JM, Cook RS.

Breast Cancer Res. 2017 Sep 8;19(1):105. doi: 10.1186/s13058-017-0893-7.

Supplemental Content

Loading ...
Support Center